nach oben

best practice onkologie

Erschienen in:

20.06.2022 | Zytostatische Therapie | CME-Topic

G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, Anämie bei Krebserkrankung

Supportivtherapieleitlinien, Teil 1

verfasst von: Hartmut Link

Erschienen in: best practice onkologie | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Infektionen bei neutropenischen Patienten nach Chemotherapie manifestieren sich meistens durch Fieber (febrile Neutropenie, FN). Zu den wichtigsten Determinanten des FN-Risikos gehören der Chemotherapietyp, die Dosisintensität und patientenspezifische Faktoren. Bei einem FN-Risiko von 20 % oder höher wird die Granulopoese nach der Therapie prophylaktisch mit G‑CSF („granulocyte colony-stimulating factor“) stimuliert. Eine Anämie sollte immer abgeklärt und falls erforderlich entsprechend ihrer Ursache bei Anämiebeschwerden behandelt werden. Wenn ein absoluter oder funktioneller Eisenmangel vorliegt, dann ist meistens eine intravenöse (i.v.) Eisensubstitution erforderlich. Erythropoesestimulierende Substanzen können nach Chemotherapie bei Hämoglobin(Hb)-Werten unter 10 g/dl (6,2 mmol/l) verwendet werden. Bei chronischer Anämie und Hb-Werten unter 8–7 g/dl (< 5,0–4,3 mmol/l) sollte die Indikation für die Transfusion von Erythrozytenkonzentraten primär anhand der individuellen klinischen Symptomatik gestellt werden.

Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J et al (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414–1422 CrossRef

(2017) CTEP: common terminology criteria for adverse events (CTCAE) v5.0., https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Zugegriffen: 26.04.2022

Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96(11):1775–1792. https://doi.org/10.1007/s00277-017-3098-3 CrossRefPubMedPubMedCentral

Sternberg CN, Mulder PH, Schornagel JH, Théodore C, Fossa SD, Oosterom ATv et al (2001) Randomized phase III trial of high–dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol no. 30924. J Clin Oncol 19(10):2638–2646. https://doi.org/10.1200/jco.2001.19.10.2638 CrossRefPubMed

Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M‑VAC chemotherapy and G‑CSF versus classic M‑VAC in advanced urothelial tract tumours. Eur J Cancer 42(1):50–54. https://doi.org/10.1016/j.ejca.2005.08.032 CrossRefPubMed

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M et al (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16(1):76–86. https://doi.org/10.1016/s1470-2045(14)71160-x CrossRefPubMed

Pfister C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B et al (2022) Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol. https://doi.org/10.1200/jco.21.02051 CrossRefPubMed

Bellmunt , von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G et al (2012) Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 30(10):1107–1113. https://doi.org/10.1200/jco.2011.38.6979 CrossRefPubMedPubMedCentral

von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068–3077. https://doi.org/10.1200/jco.2000.18.17.3068 CrossRefPubMed

10.

Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S et al (2017) Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol 35(28):3189–3197. https://doi.org/10.1200/jco.2016.72.1068 CrossRefPubMed

11.

Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C et al (2013) 2‑Weekly versus 3‑weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 14(2):117–124. https://doi.org/10.1016/s1470-2045(12)70537-5 CrossRefPubMed

12.

Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L et al (2017) Phase III study comparing a reduced dose of cabazitaxel (20 mg/m(2)) and the currently approved dose (25 mg/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol 35(28):3198–3206. https://doi.org/10.1200/jco.2016.72.1076 CrossRefPubMed

13.

Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J et al (2005) Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23(27):6549–6555. https://doi.org/10.1200/JCO.2005.19.638 CrossRefPubMed

14.

Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B et al (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17(11):3450–3456. https://doi.org/10.1200/jco.1999.17.11.3450 CrossRefPubMed

15.

de Wit R, Stoter G, Sleijfer DT, Neijt JP, ten Bokkel Huinink WW, de Prijck L et al (1998) Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 78(6):828–832. https://doi.org/10.1038/bjc.1998.587 CrossRefPubMedPubMedCentral

16.

de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD et al (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5‑day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19(6):1629–1640. https://doi.org/10.1200/jco.2001.19.6.1629 CrossRefPubMed

17.

Mulherin BP, Brames MJ, Einhorn LH (2015) Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. Am J Clin Oncol 38(4):373–376. https://doi.org/10.1097/COC.0b013e31829e19e0 CrossRefPubMed

18.

Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. (2012) Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. 118(9):2385−2393. https://doi.org/10.1002/cncr.26555.

19.

Langley RE, Carmichael J, Jones AL, Cameron DA, Qian W, Uscinska B, Howell A, Parmar M. (2005) Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol 23(33):8322−8330. https://doi.org/10.1200/JCO.2005.01.1817.

20.

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 382(9):810−821. https://doi.org/10.1056/NEJMoa1910549.

21.

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. (2022) Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 386(4):351–363. https://doi.org/10.1056/NEJMoa2115304.

22.

Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. (2018) Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol. 36(23):2395–2404. https://doi.org/10.1200/JCO.2017.76.8960.

23.

Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. (2012) Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 13(7):716-723. https://doi.org/10.1016/S1470-2045(12)70200-0.

24.

Helbekkmo N, Sundstrøm SH, Aasebø U, Brunsvig PF, von Plessen C, Hjelde HH, Garpestad OK, Bailey A, Bremnes RM; Norwegian Lung Cancer Study Group. (2007) Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer. 97(3):283–289. https://doi.org/10.1038/sj.bjc.6603869.

25.

Sugawara S, Lee JS, Kang JH, Kim HR, Inui N, Hida T, Lee KH, Yoshida T, Tanaka H, Yang CT, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Namba Y, Sumiyoshi N, Nakagawa K. (2021) Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 32(9):1137–1147. https://doi.org/10.1016/j.annonc.2021.06.004.

26.

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M (2018) IMpower150 Study Group. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 378(24):2288–2301. https://doi.org/10.1056/NEJMoa1716948

27.

Griffiths EA (2021) NCCN Guidelines Version 3.2021, Hematopoietic growth factors. NCCN Clinical Practice GUIDELINES in Oncology (NCCN Guidelines)

28.

Yarza R, Bover M, Paredes D, López-López F, Jara-Casas D, Castelo-Loureiro A et al (2020) SARS-CoV‑2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer 135:242–250. https://doi.org/10.1016/j.ejca.2020.06.001 CrossRefPubMedPubMedCentral

29.

(2021) COVID-19 patient care information—cancer treatment & supportive care. https://www.asco.org/covid-resources/patient-care-info/cancer-treatment-supportive-care. Zugegriffen: 31. Jan. 2022

30.

Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P et al (2020) Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic. J Natl Compr Cancer Netw. https://doi.org/10.6004/jnccn.2020.7610 CrossRef

31.

Aapro M, Lyman GH, Bokemeyer C, Rapoport BL, Mathieson N, Koptelova N et al (2021) Supportive care in patients with cancer during the COVID-19 pandemic. ESMO Open. https://doi.org/10.1016/j.esmoop.2020.100038 CrossRefPubMedPubMedCentral

32.

Zhang AW, Morjaria S, Kaltsas A, Hohl TM, Parameswaran R, Patel D et al (2021) The effect of neutropenia and filgrastim (G-CSF) in cancer patients with COVID-19 infection. Clin Infect Dis. https://doi.org/10.1093/cid/ciab534 CrossRefPubMedPubMedCentral

33.

Sereno M, Jimenez-Gordo AM, Baena-Espinar J, Aguado C, Mielgo X, Pertejo A et al (2021) A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 optionally treated with granulocyte-colony stimulating factor (G-CSF): a comparative analysis. Cancers. https://doi.org/10.3390/cancers13164205 CrossRefPubMedPubMedCentral

34.

Lasagna A, Muzzana M, Pedrazzoli P (2021) Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research. Immunotherapy 13(17):1369–1372. https://doi.org/10.2217/imt-2021-0219 CrossRefPubMed

35.

Cooksley T, Font C, Scotte F, Escalante C, Johnson L, Anderson R et al (2021) Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Support Care Cancer 29(2):1129–1138. https://doi.org/10.1007/s00520-020-05906-y CrossRefPubMed

36.

Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266 CrossRef

37.

Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205 CrossRef

38.

Holmes FA, O’Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clinoncol 20:727–731 CrossRef

39.

Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178–1184 CrossRef

40.

Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14(1):29–35. https://doi.org/10.1093/annonc/mdg019 CrossRefPubMed

41.

Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E et al (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5‑fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17(8):1205–1212 CrossRef

42.

Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158–3167 CrossRef

43.

Lyman GH, Reiner M, Morrow PK, Crawford J (2015) The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Ann Oncol 26(7):1452–1458. https://doi.org/10.1093/annonc/mdv174 CrossRefPubMed

44.

Supportive Therapie bei onkologischen PatientInnen – Langversion 1.0, 2016, AWMF Registernummer: 032/054OL. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Berlin: DKG, ASORS, DGHO, DEGRO. Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF), Deutschen Krebsgesellschaft e. V. (DKG) und Deutschen Krebshilfe (DKH); 2016. http://leitlinienprogramm-onkologie.de/Supportive-Therapie.95.0.html

45.

Klastersky J et al (2016) Ann Oncol 27(suppl 5):v111–v118 CrossRef

46.

Aapro MS, Bohlius J, Cameron DA, Dal LL, Donnelly JP, Kearney N et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32 CrossRef

47.

Smith TJ et al (2015) J Clin Oncol 33:3199–3212 CrossRef

48.

Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ et al (2013) Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol 31(34):4290–4296. https://doi.org/10.1200/JCO.2012.44.6229 CrossRefPubMed

49.

Edelsberg J, Weycker D, Bensink M, Bowers C, Lyman GH (2020) Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years. Curr Med Res Opin 36(3):483–495. https://doi.org/10.1080/03007995.2019.1703665 CrossRefPubMed

50.

Leonard RC, Mansi JL, Keerie C, Yellowlees A, Crawford S, Benstead K et al (2015) A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (‘SPROG’ trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN. Ann Oncol 26(12):2437–2441. https://doi.org/10.1093/annonc/mdv389 CrossRefPubMed

51.

Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z (2015) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer 23(2):525–545. https://doi.org/10.1007/s00520-014-2457-z CrossRefPubMed

52.

Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283–2295 CrossRef

53.

Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U et al (2018) Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events. J Oncol Pharm Pract 24(6):412–423. https://doi.org/10.1177/1078155217714859 CrossRefPubMed

54.

Link H, Illerhaus G, Martens UM, Salar A, Depenbusch R, Kohler A et al (2021) Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Support Care Cancer 29(5):2519–2527. https://doi.org/10.1007/s00520-020-05711-7 CrossRefPubMed

55.

Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40(3):402–407. https://doi.org/10.1345/aph.1G516 CrossRefPubMed

56.

Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y et al (2017) Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer 25(2):439–447. https://doi.org/10.1007/s00520-016-3421-x CrossRefPubMed

57.

Lyman GH, Allcott K, Garcia J, Stryker S, Li Y, Reiner MT et al (2017) The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer 25(8):2619–2629. https://doi.org/10.1007/s00520-017-3703-y CrossRefPubMed

58.

European Medicines Agency, SmPC (2007) Neulasta-Pegfilgrastim. 16.7.2007, https://www.ema.europa.eu/en/medicines/human/EPAR/neulasta. Zugegriffen: 26.04.2022

59.

Kirshner JJ, Heckler CE, Janelsins MC, Dakhil SR, Hopkins JO, Coles C et al (2012) Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J Clin Oncol 30(16):1974–1979. https://doi.org/10.1200/JCO.2011.37.8364 CrossRefPubMedPubMedCentral

60.

Kirshner JJ, McDonald MC, Kruter F, Guinigundo AS, Vanni L, Maxwell CL et al (2018) NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Support Care Cancer 26(4):1323–1334. https://doi.org/10.1007/s00520-017-3959-2 CrossRefPubMed

61.

Kwan EM, Beck S, Amir E, Jewett MA, Sturgeon JF, Anson-Cartwright L et al (2017) Impact of granulocyte-colony stimulating factor on bleomycin-induced pneumonitis in chemotherapy-treated germ cell tumors. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2017.08.012 CrossRefPubMed

62.

Laprise-Lachance M, Lemieux P, Grégoire JP (2019) Risk of pulmonary toxicity of bleomycin and filgrastim. J Oncol Pharm Pract 25(7):1638–1644. https://doi.org/10.1177/1078155218804293 CrossRefPubMed

63.

Nakagawa R, Iwamoto H, Makino T, Kadomoto S, Yaegashi H, Iijima M et al (2022) Analysis of the safety of pegfilgrastim addition in bleomycin, etoposide, and cisplatin treatment patients with germ cell tumors. Front Oncol. https://doi.org/10.3389/fonc.2021.770067 CrossRefPubMedPubMedCentral

64.

Andersen MD, Kamper P, d’Amore A, Clausen M, Bentzen H, d’Amore F (2019) The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor. Leuk Lymphoma 60(4):927–933. https://doi.org/10.1080/10428194.2018.1515939 CrossRefPubMed

65.

Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116(Suppl 7A):11S–26S. https://doi.org/10.1016/j.amjmed.2003.12.008 CrossRefPubMed

66.

Link H, Schmitz S (2013) Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany. Onkologie 36(5):266–272. https://doi.org/10.1159/000350306 CrossRefPubMed

67.

Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352(10):1011–1023. https://doi.org/10.1056/NEJMra041809 CrossRefPubMed

68.

Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322(24):1689–1692. https://doi.org/10.1056/NEJM199006143222401 CrossRefPubMed

69.

Ganz T (2011) Hepcidin and iron regulation, 10 years later. Blood 117:4425–4433 CrossRef

70.

Ganz T (2019) Anemia of Inflammation. N Engl J Med 381(12):1148–1157. https://doi.org/10.1056/NEJMra1804281 CrossRefPubMed

71.

Katodritou E, Terpos E, Zervas K, Speletas M, Kapetanos D, Kartsios C et al (2007) Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol 86:369–376 CrossRef

72.

Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H et al (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22(7):1301–1307 CrossRef

73.

Bovy C, Gothot A, Delanaye P, Warling X, Krzesinski JM, Beguin Y (2007) Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity. Nephrol Dial Transplant 22(4):1156–1162 CrossRef

74.

Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865–2874 CrossRef

75.

Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23(12):2606–2617 CrossRef

76.

Querschnitts-Leitlinien BAEK zur Therapie mit Blutkomponenten und Plasmaderivaten-Gesamtnovelle 2020. Berlin: Bundesärztekammer; 2020.

77.

Funk MB, Heiden M, Müller S et al (2021) Hämovigilanz-Bericht des Paul-Ehrlich-Instituts 2019: Auswertung der Meldungen von Reaktionen und Zwischenfällen nach § 63i AMG

78.

Szczepiorkowski ZM, Dunbar NM (2013) Transfusion guidelines: when to transfuse. ASH Educ Program Book 2013(1):638–644. https://doi.org/10.1182/asheducation-2013.1.638 CrossRef

79.

Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A et al (2013) The ASH Choosing Wisely(R) campaign: five hematologic tests and treatments to question. Blood 122(24):3879–3883. https://doi.org/10.1182/blood-2013-07-518423 CrossRefPubMed

80.

Gross I, Farmer S, Hofmann A, Ozawa S, Shander A, Aapro M (2016) Critical role of iron in epoetin alfa treatment of chemotherapy-associated anemia. J Clin Oncol. https://doi.org/10.1200/jco.2016.67.7377 CrossRefPubMedPubMedCentral

81.

Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A et al (2011) Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 378(9800):1396–1407 CrossRef

82.

Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G et al (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340:409–417 CrossRef

83.

Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C et al (2013) Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 368:11–21 CrossRef

84.

Tomic Mahecic T, Dünser M, Meier J (2020) RBC transfusion triggers: is there anything new? Transfus Med Hemother 47(5):361–369. https://doi.org/10.1159/000511229 CrossRefPubMedPubMedCentral

85.

Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C et al (2016) Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002042.pub4 CrossRefPubMedPubMedCentral

86.

Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG et al (2011) Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 365:2453–2462 CrossRef

87.

Salpeter SR, Buckley JS, Chatterjee S (2014) Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. Am J Med 127(2):124–131.e3. https://doi.org/10.1016/j.amjmed.2013.09.017 CrossRefPubMed

88.

Amato A, Pescatori M (2006) Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005033.pub2 CrossRefPubMedPubMedCentral

89.

Mortensen FV, Jensen LS, Sörensen HT, Pedersen L (2011) Cause-specific mortality associated with leukoreduced, buffy coat–depleted, or no blood transfusion after elective surgery for colorectal cancer: a posttrial 15-year follow-up study. Transfusion 51:259–263 CrossRef

90.

Castillo JJ, Dalia S, Pascual SK (2010) Association between red blood cell transfusions and development of non-hodgkin lymphoma: a meta-analysis of observational studies. Blood 116:2897–2907 CrossRef

91.

Meybohm PZ (2021) Kai: patient blood managment. https://www.patientbloodmanagement.de/. Zugegriffen: 27. Nov. 2021

92.

Leahy MF, Hofmann A, Towler S, Trentino KM, Burrows SA, Swain SG et al (2017) Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. Transfusion 57(6):1347–1358. https://doi.org/10.1111/trf.14006 CrossRefPubMed

93.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascon P, Glaspy J et al (2018) Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol 29(Suppl 4):iv96–iv110. https://doi.org/10.1093/annonc/mdx758 CrossRefPubMed

94.

Hedenus M, Adriansson M, San MJ, Kramer MH, Schipperus MR, Juvonen E et al (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122:394–403 CrossRef

95.

Chang J, Couture F, Young S, McWatters KL, Lau CY (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23(12):2597–2605 CrossRef

96.

Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258–270 CrossRef

97.

Corwin HL (2006) The role of erythropoietin therapy in the critically ill. Transfus Med Rev 20(1):27–33 CrossRef

98.

Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211–1220 CrossRef

99.

Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS et al (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26:1611–1618 CrossRef

100.

Bohlius J, Tonia T, Nuesch E, Juni P, Fey MF, Egger M et al (2014) Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Br J Cancer 111(1):33–45. https://doi.org/10.1038/bjc.2014.171 CrossRefPubMedPubMedCentral

101.

Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M et al (2019) Management of cancer-associated anemia with erythropoiesis-stimulating agents: aSCO/ASH clinical practice guideline update. J Clin Oncol 37(15):1336–1351. https://doi.org/10.1200/JCO.18.02142 CrossRefPubMed

102.

Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O et al (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003407.pub5 CrossRefPubMedPubMedCentral

103.

Goodnough LT, Skikne B, Brugnara C (2000) Erythropoietin, iron, and erythropoiesis. Blood 96(3):823–833 CrossRef

104.

Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ et al (2011) Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 29:97–105 CrossRef

105.

Aapro M, Beguin Y, Birgegard G, Gascon P, Hedenus M, Osterborg A (2011) Too-low iron doses and too many dropouts in negative iron trial? J Clin Oncol 29(17):e525–e526. https://doi.org/10.1200/JCO.2011.35.3219 (author reply e7–8) CrossRefPubMed

106.

Gafter-Gvili A, Rozen-Zvi B, Vidal L, Leibovici L, Vansteenkiste J, Gafter U et al (2013) Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia—systematic review and meta-analysis of randomised controlled trials. Acta Oncol 52(1):18–29. https://doi.org/10.3109/0284186X.2012.702921 CrossRefPubMed

Titel: G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, Anämie bei Krebserkrankung
Supportivtherapieleitlinien, Teil 1
verfasst von: Hartmut Link
Publikationsdatum: 20.06.2022
Verlag: Springer Medizin
Schlagwörter: Zytostatische Therapie
Filgrastim
Epoetin alfa
Anämien
Epoetin alfa
Neutropenie
Eisenmangel
Filgrastim
Epoetin alfa
Pegfilgrastim
Pegfilgrastim
Erschienen in: best practice onkologie / Ausgabe 6/2022
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI: https://doi.org/10.1007/s11654-022-00398-0

Neu im Fachgebiet Onkologie

08.12.2023 | Magenkarzinom | Nachrichten

Springer Medizin

G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, Anämie bei Krebserkrankung

Supportivtherapieleitlinien, Teil 1

Zusammenfassung

Neu im Fachgebiet Onkologie

Sintilimab mit positiven Ergebnissen bei fortgeschrittenem Magenkrebs

Erhöhtes Risiko für Aneurysmen und Dissektionen unter VEGFR-TKI

Blinde Flecken in der Hautkrebsvorsorge

Krebs im Kopf- und Halsbereich: Überlebensnachteil in Ostdeutschland

Update Onkologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

Editorial

Patienten mit Uro- und Kolostoma in der Rehabilitation

Wichtige Studien vom ASH 2021

Mehr Therapietreue durch Mitwirken der Patienten

Palliativversorgung braucht gemeinsames Denken und Handeln

Chirurgische Therapie von Tumoren im Bereich des Ober- und Unterkiefers

Neu im Fachgebiet Onkologie

Sintilimab mit positiven Ergebnissen bei fortgeschrittenem Magenkrebs

Erhöhtes Risiko für Aneurysmen und Dissektionen unter VEGFR-TKI

Blinde Flecken in der Hautkrebsvorsorge

Krebs im Kopf- und Halsbereich: Überlebensnachteil in Ostdeutschland

Update Onkologie